| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 30(6); 1998 > Article
Journal of the Korean Cancer Association 1998;30(6): 1240-1248.
A Comparison of the Acute Antiemetic Effect of Tropisetron with Ondansetron in Patients Receiving Cisplatin
Sung Tae Cho, Bo Kwon Hwang, Chan Kyu Kim, Bong Min Ko, Sung Han Bae, Jong Dae Bong, Cheol Woo Lee, Sung Kyu Park, Jong Ho Won, Seung Ho Baick, Dae Sik Hong, Hee Sook Park
1Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.
2Institute for Clinical Molecular Biology Reserch, Soonchunhyang University College of Medicine, Seoul, Korea.
Tropisetron, a new specific 5-hydroxytryptamine3 (5-HT3) receptor antagonist, is an effective antiemetic agent in the control of chemotherapy induced emesis with a long half life and bioavailablity. We compared the efficacy and safefy of Tropisetron and ondansetron to control emesis induced by highly emetogenic chemotherapeutics (cisplatin > or = 50 mg/m(2)).
Twenty-one patients were administered in a randomized, open, crossover study and received either tropisetron plus dexamethasone or ondansetron plus dexamethasone during two successive cycles of chemotherapy.
Control of acute emesis with either tropisetron or ondansetron was 100% vs 95.2%, and 80.9% vs 76.2% in control of delayed emesis. Both severity and duration of nausea showed no statistically significant difference between tropisetron and ondansetron. Poor appetite and headache were most common side effects in both groups.
There was no significant difference in efficacy for control of emesis and nausea between tropisetron and ondansetron in cisplatin-based chemotherapy.
Key words: Tropisetron;Ondansetron;Cisplatin;Emesis
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI